FORMULATION AND EVALUATION OF SUSTAINED RELEASE TABLET OF DILTIAZEM HYDROCHLORIDE

Diltiazem HCl is a calcium ion channel inhibitor. The capacity to hinder the convergence of calcium ion present in of cardiac and vascular smooth muscle during membrane depolarization is accepted to be its therapeutic impact. It is broadly utilized in the treatment of a few kinds of cardiovascular disorders. For accomplishing better drug viability, unwavering quality success within the leading edge pharmaceutical structure, and targeted analysis, sustained-release drug delivery has touched toward changing into gauges. The biggest offer of drug delivery frameworks, for example, up to 80% of all the medication records to the OSRDD (Oral Sustained Release Drug Delivery). Sustained releases tablets of diltiazem HCl was planned to utilize Hydroxypropyl methylcellulose (HPMC 643), and povidone in various ratios, the extended-release conduct of fabricated tablets were then assessed. Sustained-release diltiazem HCl tablets were made by the direct compression method. The formulation was streamlined based on various tablet properties and drug release design in-vitro release profile. The subsequent formulation created tablets with required hardness, weight uniformity, and friability. The aftereffect of in-vitro dissolution study demonstrated that formulation F5 is the most suitable formulation as it displays drug release design for any longer period of time. An increase in the drug release profile of the drug was seen on expanding polymer proportion.